Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
A: Placebo to match Donepezil and MK-3134+ Placebo to match Scopolamine · 1 trial · 1 indication
Participants learned a hidden pathway through a maze (10 x 10 grid of tiles on a computer touch screen) using step-by-step guess, with trial and error feedback after each step. Once the pathway was learned, participants repeated the same pathway four more times. The number of pathway errors was used to indicate the level of cognitive function.
| Arm | Type | Description |
|---|---|---|
| A, B, D, E, C | EXPERIMENTAL | Participants received treatment A, B, D, E, C for Periods 1, 2, 3, 4, and 5, respectively. |
| B, C, E, A, D | EXPERIMENTAL | Participants received treatment B, C, E, A, D for Periods 1, 2, 3, 4, and 5, respectively. |
| C, D, A, B, E | EXPERIMENTAL | Participants received treatment C, D, A, B, E for Periods 1, 2, 3, 4, and 5, respectively. |
| D, E, B, C, A | EXPERIMENTAL | Participants received treatment D, E, B, C, A for Periods 1, 2, 3, 4, and 5, respectively. |
| E, A, C, D, B | EXPERIMENTAL | Participants received treatment E, A, C, D, B for Periods 1, 2, 3, 4, and 5, respectively. |
| A, C, B, E, D | EXPERIMENTAL | Participants received treatment A, C, B, E, D for Periods 1, 2, 3, 4, and 5, respectively. |
| B, D, C, A, E | EXPERIMENTAL | Participants received treatment B, D, C, A, E for Periods 1, 2, 3, 4, and 5, respectively. |
| C, E, D, B, A | EXPERIMENTAL | Participants received treatment C, E, D, B, A for Periods 1, 2, 3, 4, and 5, respectively. |
| D, A, E, C, B | EXPERIMENTAL | Participants received treatment D, A, E, C, B for Periods 1, 2, 3, 4, and 5, respectively. |
| E, B, A, D, C | EXPERIMENTAL | Participants received treatment E, B, A, D, C for Periods 1, 2, 3, 4, and 5, respectively. |
| Name | Type | Description |
|---|---|---|
| A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine | DRUG | Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of placebo to match scopolamine SQ. |
| B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg | DRUG | Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of scopolamine 0.5 mg SQ. |
| C: MK-3134 25 mg + Scopolamine 0.5 mg | DRUG | A single dose of MK-3134 PO 25 mg, plus a single dose of scopolamine SQ 0.5 mg. |
| D: Donepezil 10 mg + Scopolamine 0.5 mg | DRUG | A single dose of donepezil 10 mg PO, plus a single dose of scopolamine 0.5 mg SQ. |
| E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg | DRUG | A combination of single doses of all active drugs: donepezil 10 mg and MK-3134 25 mg PO, plus scopolamine, SQ. |
Participants were eligible for inclusion in the study who were: * Male between 18 and 40 years of age. * Non-smokers, in good health (as defined in protocol), and were willing to follow study-related procedures. Participants were not eligible for inclusion in the study if they: * Had a history of...
It is a placebo comparator used in a Merck Phase 1 crossover study in dementia research. The study combined placebo matching donepezil and MK-3134 with placebo matching scopolamine to provide a control arm for evaluating cognitive effects. It contains no active drug ingredient.
Merck & Company, Inc., which trades under the ticker MRK, is the developer listed for this placebo comparator. It was used as the control material in a Merck-sponsored Phase 1 study of donepezil and MK-3134 in dementia research.
It was used in a Phase 1 clinical trial, and that study is completed. It is a placebo comparator rather than an investigational therapeutic agent, so it is not being developed as a treatment and is not FDA approved for any indication.
It was used in NCT01181310, a placebo-controlled crossover study evaluating donepezil and MK-3134 for reversal of cognitive impairment associated with scopolamine administration. The Phase 1 trial enrolled 31 healthy male volunteers aged 18 years and older and is completed.